Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)

Koselugo® (selumetinib) is the first FDA approved drug indicated for the treatment of neurofibromatosis type 1 (NFI). Credit: Astrazeneca.



  • Koselugo
  • Koselugo
  • Koselugo